Interview: Real World Evidence’s Commercial Facet
Executive Summary
Senior QuintilesIMS officials tell Scrip that harnessing real world evidence (RWE) insights on the commercial side is not quite the “norm” yet across pharmaceutical companies, although it can provide up to $1bn in value across lifecycle. They also explain the growing significance of RWE in the Middle East.
You may also be interested in...
Why Pharma Doesn't Always Keep Phase IV Promises In India
Are drug firms being lax when it comes to Phase IV studies in markets like India or are certain arbitrarily determined regulatory requirements largely to blame? Scrip delves into the issue.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet